CN114907484A - A strong anti-new crown mutation strain includes four subtypes of bispecific humanized antibody of Ormcken - Google Patents
A strong anti-new crown mutation strain includes four subtypes of bispecific humanized antibody of Ormcken Download PDFInfo
- Publication number
- CN114907484A CN114907484A CN202210421123.7A CN202210421123A CN114907484A CN 114907484 A CN114907484 A CN 114907484A CN 202210421123 A CN202210421123 A CN 202210421123A CN 114907484 A CN114907484 A CN 114907484A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 241001678559 COVID-19 virus Species 0.000 claims description 16
- 241000711573 Coronaviridae Species 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000003389 potentiating effect Effects 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 108010075254 C-Peptide Proteins 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940125644 antibody drug Drugs 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 241001112090 Pseudovirus Species 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 238000010276 construction Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108010066342 Virus Receptors Proteins 0.000 description 9
- 102000018265 Virus Receptors Human genes 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102100031673 Corneodesmosin Human genes 0.000 description 8
- 101710139375 Corneodesmosin Proteins 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000013638 trimer Substances 0.000 description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 108070000030 Viral receptors Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003757 Atypical pneumonia Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000711902 Pneumovirus Species 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000013639 protein trimer Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700023317 Coronavirus Receptors Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960004965 begelomab Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 229940051283 regdanvimab Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Abstract
The invention discloses a single chain bispecific antibody capable of resisting new corona and mutant strains thereof, which is formed by combining two new corona human source specific antibodies, and realizes strong protection on all subtypes of an Onckronk mutant strain, namely BA.1 (IC 500.04 mu g/ml), BA.2 (IC 500.05 mu g/ml), BA.3 (IC 500.04 mu g/ml) and BA.1.1 (IC 500.08 mu g/ml). The single-chain bispecific antibody of the invention is used as an effective antibody drug for efficiently resisting all the existing new crown mutation strains and future new crown mutation strains.
Description
Technical Field
The invention belongs to the technical field of biological medicine, and particularly relates to a strong anti-new crown mutation strain, including four subtypes of double-specific humanized antibody of Ormcken.
Background
With the continuous spread of new coronavirus in people, various variant strains bring great threat to the vaccine immunity defense line constructed globally. The emergence of the variant of Omicron, with its powerful immune escape capacity, has raised an unprecedented concern about the effectiveness of anti-body therapies and vaccines. Therefore, the development of broad-spectrum antibodies against the omitron variants is of crucial importance. However, the rate-limiting step of broad-spectrum antibody screening is a problem to be solved that the immunogenicity of conserved epitopes is poor, resulting in few candidate antibodies. The mainstream human-derived broad-spectrum antibody research idea is to improve the generation probability of the broad-spectrum antibody of a subject by immunogen transformation, sequential immunization and other modes, and simultaneously improve the mining capability of the trace broad-spectrum antibody by using the mode of 'first generation and then mining' of single cells and high-throughput sequencing, for example, the S309 antibody is an excellent case of the idea [1] Furthermore, the dorsal epitope of the Receptor Binding Domain (RBD) of the spike protein to which S309 binds, recently proved to be a conserved epitope minimally affected by the Omicron variant [2] 。
In addition to mabs, mild symptoms in patients at high risk for COVID-19 would be treated by the combination of two mAb antibodies, however effects similar to this mAb combination could be achieved by a single bispecific antibody (BsAb). It is a specific antibody designed to bind two different antigens simultaneously based on the unique structure of the antibody, and the theory of BsAb antibody was first proposed by Nisonoff and his co-workers in 1960 [6] Later, scholars proposed BsAb in 1964, which was produced with antibodies in the eighty-ninety yearsThe continuous development of physics and antibody engineering continuously solves the problems of BsAb molecules in the aspects of adhesion, crosslinking, assembly and the like [7] The first bispecific antibody drug for treating malignant ascites disease in the world was approved until 2009 [8] In the application of bispecific antibody drugs, 90% of them are used for cancer treatment, and in recent years, the studies of bispecific antibody drugs in infection, inflammation, neurodegenerative diseases, ophthalmology, metabolic diseases, etc. have been increasing, and these studies provide certain basis for developing antibody drugs for treating BsAb of covi-19.
BsAb is mainly classified into two categories according to structure: bispecific antibodies with FC regions (IgG-like bispecific antibodies) and bispecific antibodies without FC regions (non-IgG-like bispecific antibodies). Bispecific antibodies containing Fc regions retain the structure of traditional monoclonal antibodies, having two Fab regions and one Fc region. However, unlike conventional monoclonal antibodies, the two fabs bind different antigens. The antibodies mainly comprise Triomabs, DVD-Ig, 2in 1-IgG, kih IgG, CrossMAb and the like; bispecific antibodies without an Fc region lack an Fc region, consisting of the VH and VL regions of both antibodies or consisting of Fab fragments. Such bispecific antibodies are mainly BiTE, DART, TandAbs, bi-Nanobody, and the like.
Based on this, related studies have reported some BsAbs for treating COVID-19. The first BsAb against SARS-CoV-2 was constructed by linking a non-neutralizing binding agent to a neutralizing binding agent in a bispecific scaffold. In particular to [9] The authors first identified fabs that bind to RBDs but not ACE2 by phage display and then assembled them into specific IgG scaffolds with human variable heavy chain (VH) binders that block ACE2, producing VH/Fab bsAb-Bis-4(VH B01, Fab D01), where mab Fab D01 alone had no neutralizing effect on SARS-CoV-2, but Bis-4 was designed and constructed to be 20-25 fold higher in virus neutralizing titer and SARS-CoV-2 could reach 0.107 nm. The second is IgG-like BsAb-CoV-X2 designed by using the knob-into-hole technology, which is designed by combining two monoclonal antibodies C121 and C135 separated from convalescent patients of COVID-19,with the structure domain RBD of S protein of SARS-CoV-2 as target, CoV-X2 molecule can neutralize WT (0.9nm), alpha (0.2nm), beta (12nm), gamma (2.1nm) and other strains [10] . The third is DVD-Ig-G BsAb, in which three effective BsAb molecules are screened [11] (CV1206_521_ GS, CV503_664_ EL and CV503_521_ GS) wherein GS indicates that two intermolecular light and heavy chains are combined at GGGGSGGGGSGGGG linker, EL indicates that the variable region and the constant region of the light chain are connected by QPKAAPSVTLFPP, the variable region and the constant region of the heavy chain are connected by STKGPSVFPLAP, and mAbs CV503, CV521, CV664 and CV1206 are all isolated from plasma cells and memory cells of patients with COVID-19 and target the RBD domain or NTD domain of the S protein respectively, can neutralize strains such as WT, alpha, beta, gamma, etc., the value of IC50 is less than 0.1ng/mL, and the neutralization is improved by about 10-100 times compared with the mAb used alone. The fourth is bi-Nanobody-BsAb-Nb15-NH-Nb15 [12] It is a targetable RBD and human serum albumin screened from the nano-neutralizing antibody database of alpaca, Nb15-NbH-Nb15 shows a neutralizing effect of unit ng/ml on WT and Delta variants of SARS-CoV-2, has a longer half-life in vivo, and in addition Nb15-NbH-Nb15 provides effective protection for prevention and treatment of SARS-CoV-2 infection of transgenic hACE2 mice by intranasal administration. The fifth is also IgG-like BsAb-Clone 2 [13] It is a neutralizing antibody obtained by sequencing high-throughput single-cell BCR, and has strong neutralizing effect on WT and B.1.617.2-Delta variant. The sixth is crossMAb-BsAb, targeted at target DDP4 (co-receptor of ACE 2) and RBD, Regdanvimab and Begelomab (mAb) were identified as D614G mutant S proteins blocking the SARSCoV-2 and host DPP4 receptors, respectively, and were modified to prevent heavy and light chain mismatches using KIH (Knobs into holes) and crossMAb techniques [14] . The seventh belongs to a nano BsAb which can induce the S protein to form a trimer, prevent the S protein from being combined with a host cell surface receptor ACE2 and neutralize mutant strains of WT, beta, Delta and the like [15] . The last BsAb15 was designed based on a pair of noncompetitive human neutralizing antibodies (B38 and H4) that block the binding of SARS-CoV-2 to its receptor ACE2 [16] The bsAb15 has higher neutralization efficiency than these mAb antibodies, leading to and retaining the neutralizing effect on most SARS-CoV-2 neutralizing capacity of the relevant variant (stronger neutralizing activity against Delta variants).
Reference to the literature
1.Pinto,D.,et al.,Cross-neutralization of SARS-CoV-2by a human monoclonal SARS-CoV antibody.Nature,2020.583(7815):p.290-295.
2.Zhou,T.,et al.,Structural basis for potent antibody neutralization of SARS-CoV-2variants including B.1.1.529.Science,2022:p.eabn8897.
3.Barnes,C.O.,et al.,SARS-CoV-2neutralizing antibody structures inform therapeutic strategies.Nature,2020.588(7839):p.682-687.
4.Hansen,J.,et al.,Studies in humanized mice and convalescent humans yield a SARS-CoV-2antibody cocktail.Science,2020.369(6506):p.1010-1014.
5.Liu,H.,et al.,Cross-Neutralization of a SARS-CoV-2Antibody to a Functionally Conserved Site Is Mediated by Avidity.Immunity,2020.53(6):p.1272-1280.e5.
6.Yuan,M.,et al.,A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2and SARS-CoV.Science,2020.368(6491):p.630-633.
7.Kipriyanov,S.M.,et al.,Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.J Mol Biol,1999.293(1):p.41-56.
6.Nisonoff,A.,F.C.Wissler,and L.N.Lipman,Properties of the major component of a peptic digest of rabbit antibody.Science,1960.132(3441):p.1770-1.
7.Labrijn,A.F.,et al.,Bispecific antibodies:a mechanistic review of the pipeline.Nat Rev Drug Discov,2019.18(8):p.585-608.
8.Heiss,M.M.,et al.,The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer:Results of a prospective randomized phase II/III trial.Int J Cancer,2010.127(9):p.2209-21.
9.Lim,S.A.,et al.,Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.MAbs,2021.13(1):p.1893426.
10.De Gasparo,R.,et al.,Bispecific IgG neutralizes SARS-CoV-2variants and prevents escape in mice.Nature,2021.593(7859):p.424-428.
11.Cho et al.,eabj5413(2021)Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2variants of concern.Sci.Transl.Med.,2021.10.5413.
12.Wu,X.,et al.,A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2infection via intranasal administration.Cell Rep,2021.37(3):p.109869.
13.Peng,L.,et al.,Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.bioRxiv,2021.
14.Ojha,R.,et al.,Designing of a bispecific antibody against SARS-CoV-2spike glycoprotein targeting human entry receptors DPP4 and ACE2.Hum Immunol,2022.
15.Hanke,L.,et al.,A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2in vivo.Nat Commun,2022.13(1):p.155.
16.Li,Z.,et al.,An engineered bispecific human monoclonal antibody against SARS-CoV-2.Nat Immunol,2022.23(3):p.423-430。
Disclosure of Invention
The bispecific antibody is successfully constructed by utilizing the characteristics of different epitopes of the IMCAS-123 antibody and the IMCAS-364 antibody and based on the characteristic of a long Linker efficiently producing Monomer form in a reference document. The affinity of the mutant strain is improved by 5-10 times compared with the original IMCAS-123 and IMCAS-364 for the receptor binding domains of different variants. Thus, the present invention has been completed.
The invention provides a bispecific humanized antibody of a potent anti-new crown mutation strain, which is formed by connecting a first antibody heavy chain, a second antibody light chain and a first antibody heavy chain by a connecting peptide linker. Wherein the content of the first and second substances,
the heavy chain variable region of the first antibody (IMCAS-364) comprises the CDR1 amino acid sequence: SEQ ID NO. 1: GFTFSRYG; the CDR2 amino acid sequence is SEQ ID NO. 2: IWYDGSNK; the CDR3 amino acid sequence is SEQ ID No. 3: AKQEGTYCSGGSCYSGLDY, respectively;
the variable region of the light chain of the first antibody (IMCAS-364) comprises the CDR1 amino acid sequence of SEQ ID No. 4: QSISSY; the CDR2 amino acid sequence is SEQ ID No. 5: AAS; the CDR3 amino acid sequence is SEQ ID NO. 6: QQSYSTPLT are provided.
The variable region of the heavy chain of the second antibody (IMCAS-123) comprises the CDR1 amino acid sequence: SEQ ID NO. 7: GFTFSSYA; the CDR2 amino acid sequence is SEQ ID NO. 8: ISGSGGST; the CDR3 amino acid sequence is SEQ ID NO. 9: AKDHLITMVQPEYFHHW, respectively; further, the CDR3 amino acid sequence is mutated, namely AKDHLSTMVQPEYFHHW、AKDHLMTMVQPEYFHHW、AKDHLITLVQPEYFHHW、AKDHFITMVQPEYFHHW、AKDHFITMVQPEYFYHW。
The variable region of the light chain of the second antibody (IMCAS-123) comprises the CDR1 amino acid sequence of SEQ ID No. 10: QGISRW; the CDR2 amino acid sequence is SEQ ID NO. 11: AAG; the CDR3 amino acid sequence is SEQ ID No. 12: CQADSSF;
more preferably, the variable region amino acid sequence of the heavy chain of said first antibody (IMCAS-364) is SEQ ID NO. 13: QVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSAS, respectively; the variable region amino acid sequence of the light chain of the second antibody (IMCAS-364) is SEQ ID No. 14: DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKG are provided.
The variable region amino acid sequence of the heavy chain of the second antibody (IMCAS-123) is SEQ ID NO. 15: QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSAS, respectively; the variable region amino acid sequence of the light chain of the second antibody (IMCAS-123) is SEQ ID NO. 16: DIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKG are provided.
Specifically, the first antibody heavy chain, the linker1, the second antibody light chain, the linker2, the second antibody heavy chain, the linker1 and the first antibody light chain are connected in sequence in the above order, and more preferably, the connection mode is that the first antibody heavy chain, the linker1, the second antibody light chain, the linker2 and the second antibody heavy chain are connected in sequence.
Preferably, the amino acid sequence of Linker1 is SEQ ID NO. 17: RADAAAAGGPGS, respectively; the amino acid sequence of Linker2 is SEQ ID NO. 18: RADAAAAGGGGSGGGGSGGGGSGGGGS are provided.
Preferably, the amino acid sequence of the bispecific humanized antibody of the potent anti-new crown mutation strain is SEQ ID NO. 19:
QVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSASRADAAAAGGPGSDIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKGRADAAAAGGGGSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSASRADAAAAGGPGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKGTKGPSVTSGQAGQ
further preferably, the bispecific humanized antibody against the new crown mutation strain further comprises a signal peptide, and therefore the connection sequence is formed by connecting the signal peptide, a first antibody heavy chain, a linker1, a second antibody light chain, a linker2, a second antibody heavy chain, a linker1 and the first antibody light chain in sequence. In an embodiment the amino acid sequence of the signal peptide is SEQ ID NO. 20: METDTLLLWVLLLWVPGSTGD is added. Further, it comprises a tag sequence for isolation and purification, such as 6 × His tag.
Most preferably, the amino acid sequence of the bispecific humanized antibody against the novel crown mutation strain is SEQ ID No. 21:
METDTLLLWVLLLWVPGSTGDQVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSASRADAAAAGGPGSDIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKGRADAAAAGGGGSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSASRADAAAAGGPGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKGTKGPSVTSGQAGQHHHHHH*
the invention also provides the coding nucleic acid of the bispecific humanized antibody of the high-efficiency anti-new crown mutation strain. Preferably, the nucleotide sequence thereof is SEQ ID No. 22:
ATGCAGGTGCAGCTGCAAGAGAGCGGCGGCGGTGTCGTGCAGCCTGGCCGGAGCCTGAGACTGAGCTGCGCCGCTAGCGGCTTCACCTTTTCTAGATACGGCATGCACTGGGTGAGACAGGCTCCTGGCAAGGGGCTGGAATGGGTGGCCGTGATCTGGTACGACGGCTCCAACAAGTACTACGCCGATAGCGTGAAGGGCAGATTCACCATCTCCCGGGACAACAGCAAAAATACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGACGACACGGCCGTGTACTACTGCGCCAAACAGGAGGGCACATATTGCAGCGGCGGAAGCTGCTACAGCGGACTGGACTACTGGGGACAGGGCACACTGGTGACCGTGAGCAGCGCTTCTCGGGCCGATGCCGCTGCTGCCGGCGGCCCCGGCTCTGATATCCAGATGACCCAGTCCCCAAGCTCTGTGAGCGCCTCTGTTGGCGACAGCGTGACAATCACATGCCGCGCCAGCCAGGGCATCAGCAGATGGCTGGCCTGGTATCAGCAAAGACCTGGCAAGGCCCCTAAACTGCTGATCTACGCCGCTGGGAACCTGGAAACCGGCGTGCCTAGCAGGTTCAGCGGCTCCGGTAGCGGCACCGACTTTACACTTACCATCAGCGACCTGCAAGCAGAGGACTTCGCCACATACTATTGTCAGCAGGCCGACTCATTCCCCCTGACCTTCGGCGGCGGCACAAAGGTGGACATTAAGGGCAGAGCCGACGCCGCGGCCGCCGGCGGAGGAGGCTCGGGCGGCGGAGGTAGCGGCGGCGGAGGTTCTGGAGGCGGCGGCTCACAGGTGCAGCTGGTCGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTCAGACTGAGCTGTGCCGCCAGCGGATTCACCTTTAGTAGCTACGCCATGAGCTGGGTTAGACAGGCCCCTGGCAAAGGCCTGGAGTGGGTGTCCGCCATCAGCGGCTCCGGAGGCAGCACCTACTACGCCGACAGCGTCAAGGGCAGATTTACCATCAGCAGAGATAATAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTCCGGGCCGAAGATACCGCTGTGTACTACTGTGCCAAGGACCACCTGATCACCATGGTGCAGCCCGAGTACTTCCACCACTGGGGCCAAGGAACCCTGGTGACAGTGTCTTCCGCCAGCAGAGCCGATGCCGCCGCCGCCGGCGGACCCGGCGACATTCAGATGACACAGAGCCCTTCTTCTCTGTCTGCTTCTGTCGGCGATCGGGTGACCATCACCTGCAGAGCCAGCCAGAGCATCTCCAGCTACCTGAACTGGTACCAGCAAAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACGCGGCCTCTAGCCTGCAGAGCGGAGTGCCCAGCCGGTTCAGCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAACCTGAGGACTTCGCCACATACTACTGCCAGCAGAGTTATAGCACACCTCTGACCTTCGGCGGTGGAACAAAGGTGGACATCAAGGGTACCAAGGGCCCTAGCGTGACCAGCGGCCAGGCCGGC。
or SEQ ID NO. 23:
ATGGAAACTGACACCCTGCTGCTCTGGGTGCTGCTGCTGTGGGTGCCAGGCTCTACCGGAGATCAGGTGCAGCTGCAAGAGAGCGGCGGCGGTGTCGTGCAGCCTGGCCGGAGCCTGAGACTGAGCTGCGCCGCTAGCGGCTTCACCTTTTCTAGATACGGCATGCACTGGGTGAGACAGGCTCCTGGCAAGGGGCTGGAATGGGTGGCCGTGATCTGGTACGACGGCTCCAACAAGTACTACGCCGATAGCGTGAAGGGCAGATTCACCATCTCCCGGGACAACAGCAAAAATACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGACGACACGGCCGTGTACTACTGCGCCAAACAGGAGGGCACATATTGCAGCGGCGGAAGCTGCTACAGCGGACTGGACTACTGGGGACAGGGCACACTGGTGACCGTGAGCAGCGCTTCTCGGGCCGATGCCGCTGCTGCCGGCGGCCCCGGCTCTGATATCCAGATGACCCAGTCCCCAAGCTCTGTGAGCGCCTCTGTTGGCGACAGCGTGACAATCACATGCCGCGCCAGCCAGGGCATCAGCAGATGGCTGGCCTGGTATCAGCAAAGACCTGGCAAGGCCCCTAAACTGCTGATCTACGCCGCTGGGAACCTGGAAACCGGCGTGCCTAGCAGGTTCAGCGGCTCCGGTAGCGGCACCGACTTTACACTTACCATCAGCGACCTGCAAGCAGAGGACTTCGCCACATACTATTGTCAGCAGGCCGACTCATTCCCCCTGACCTTCGGCGGCGGCACAAAGGTGGACATTAAGGGCAGAGCCGACGCCGCGGCCGCCGGCGGAGGAGGCTCGGGCGGCGGAGGTAGCGGCGGCGGAGGTTCTGGAGGCGGCGGCTCACAGGTGCAGCTGGTCGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTCAGACTGAGCTGTGCCGCCAGCGGATTCACCTTTAGTAGCTACGCCATGAGCTGGGTTAGACAGGCCCCTGGCAAAGGCCTGGAGTGGGTGTCCGCCATCAGCGGCTCCGGAGGCAGCACCTACTACGCCGACAGCGTCAAGGGCAGATTTACCATCAGCAGAGATAATAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTCCGGGCCGAAGATACCGCTGTGTACTACTGTGCCAAGGACCACCTGATCACCATGGTGCAGCCCGAGTACTTCCACCACTGGGGCCAAGGAACCCTGGTGACAGTGTCTTCCGCCAGCAGAGCCGATGCCGCCGCCGCCGGCGGACCCGGCGACATTCAGATGACACAGAGCCCTTCTTCTCTGTCTGCTTCTGTCGGCGATCGGGTGACCATCACCTGCAGAGCCAGCCAGAGCATCTCCAGCTACCTGAACTGGTACCAGCAAAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACGCGGCCTCTAGCCTGCAGAGCGGAGTGCCCAGCCGGTTCAGCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAACCTGAGGACTTCGCCACATACTACTGCCAGCAGAGTTATAGCACACCTCTGACCTTCGGCGGTGGAACAAAGGTGGACATCAAGGGTACCAAGGGCCCTAGCGTGACCAGCGGCCAGGCCGGCCAGCACCATCACCACCACCACTGA。
the invention also provides an expression vector and a recombinant cell of the nucleic acid.
The invention also provides the application of the bispecific humanized antibody of the strong anti-new crown mutation strain in the preparation of drugs for treating diseases caused by new crown viruses, wherein the new crown viruses are selected from SARS-CoV-2 and SARS strains. More preferably, the SARS-CoV-2 is selected from the group consisting of a prototype strain, an alpha variant, a beta variant, a delta variant, a gamma variant, and an Onck Ron variant (more specifically, subtypes BA.1, BA.2, BA.3, and BA.1.1).
Accordingly, the present invention provides a pharmaceutical composition for the above use, wherein the bispecific humanized antibody against the novel crown mutation strain is a potent antibody against the novel crown mutation strain as an active ingredient. Preferably, a pharmaceutically acceptable carrier is also included, as well as in combination with other drugs.
The invention successfully constructs the bispecific antibody by utilizing the characteristics of different epitopes of the IMCAS-123 antibody and the IMCAS-364 antibody. The neutralization effect is greatly improved for different subtypes of Omicron. The invention has realized that the strong protection to all subtypes of the Ormckrozen mutant strain comprises BA.1(0.04 mu g/ml), BA.2(0.05 mu g/ml), BA.3(0.04 mu g/ml) and BA.1.1(0.08 mu g/ml), is an effective antibody drug for efficiently resisting all existing and future new crown mutant strains, and thus has completed the invention.
Drawings
FIG. 1 shows the purification results of the dual specific antibody Tand ab123-64 protein of the present invention.
FIG. 2 the affinity of the bispecific antibody Tandab123-64 to the novel coronavirus receptor binding domain protein.
FIG. 3 shows the neutralization experiment of the bispecific antibody Tand ab123-64 and SARS-CoV-2 pseudovirus.
Detailed Description
In order to break through the traditional mode of 'generation before screening' and quickly focus candidate antibodies on conserved epitopes, the invention utilizes antigen subtraction screening of a spike protein receptor binding domain of a prototype strain and a spike protein receptor binding domain of a Beta variant strain to quickly focus antibodies of conserved target positions of ClassIII and ClassVI in epitope classification on a platform for screening weak immunogenic antibodies based on a phage antibody library display technology, and successfully separates in vitro fully human antibodies which are combined on different epitopes of the receptor binding domain and can realize broad-spectrum neutralization on VOCs. Wherein, the affinity of the IMCAS-123 antibody to prototype strains, Alpha, Beta, Delta and Omicron variant strains reaches nM level (see Chinese patent application 202210228772.5), the neutralization to pseudoviruses of high-transmission-force Omicron variant strains reaches 0.04 mu g/ml, and the antibody can neutralize all three subtypes of Omicron BA.1BA.2BA.3. Structural biology demonstrated that IMCAS-123 binds to a similar epitope as REGN10987, but IMCAS-123 does not bind to Q498(Omicron mutated at this site), and furthermore both IMCAS-123 and S309 bind to the T345, L441 conserved site, and additionally to the Y351 conserved site. Another broad-spectrum antibody IMCAS-364 was also selected, which also has nM affinity for the prototype strain, Alpha, Beta, Delta, and Omicron (see, Chinese patent application 202210295369.4).
Through the known epitope antibody competition experiment, the fact that IMCAS-364 binds to a rare target position on the inner side of RBD and does not compete with the receptor ACE2 (different from the fact that the COVA1-16 antibody competes with ACE 2) is the first time that an antibody binding to the target position is found, and the new coronavirus can be neutralized without competing with ACE2 (different from the fact that the CR3022 antibody only neutralizes SARS). The IMCAS-364 has good potential for developing a bi-specific antibody by matching an RBM binding antibody with a receptor binding domain dorsal binding antibody, and meanwhile, the IMCAS-364 has the capacity of binding SARS virus with the affinity of nM level, so that the IMCAS-364 is a good development source of the generic SARS coronavirus neutralizing antibody.
By utilizing the characteristics of different epitopes of IMCAS-123 and IMCAS-364 antibodies, according to the characteristic of the molecular distance of 90 angstroms of three RBD epitopes on the surface S protein trimer of the new coronavirus, the span of the traditional IgG1 form antibody is considered to be 150 angstroms, and bivalent combination cannot be formed in one trimer molecule. By adopting a construction mode of single-chain diabody, the theoretical molecular length of the single-chain diabody is 60-70 angstroms, the single-chain diabody can be effectively embedded in a trimer, and in the process of combining virus and a receptor, two RBDs are combined by the bispecific molecules to lock the conformational change, so that invasion blocking is realized. In the construction process, based on a reference for constructing a Tand form tetramer molecule in an escherichia coli system, the defect that a large number of single chains are generated by a long Linker to cause double chains to be incapable of being efficiently paired is mentioned [7], and by reversely utilizing the defect of the single chain self-reverse-folding, based on two light-heavy chain variable region sequences of known IMCAS-123 and IMCAS-364, the key part of the construction is mapped as EcoRI-signal peptide-364 VH-Linker1-123VL-Linker2-123VH-Linker1-364VL-SfiI-6 xHis-stop codon-XhoI, and the construction adopts a gene synthesis mode and is connected into a pcags expression vector through EcoRI and XhoI. A single-chain bispecific antibody with the size of 55kDa which can be expressed in mammalian cells is successfully constructed, the purification is simple, and the plasmid forward yield reaches 22 mg/L.
The present invention is illustrated by the following specific examples, which are not intended to limit the invention. The experimental methods are all conventional methods as explained in Yuan Special Specification.
EXAMPLE I construction of bispecific antibody Tandab123-64
This example illustrates linking IMCAS-123 in tandem with the heavy and light chain variable regions of the IMCAS-364 antibody by a linker in the following order: 364VH-linker1-123VL-linker2-123VH-linker1-364 VL.
The specific construction steps are as follows:
by utilizing the characteristics of different epitopes of IMCAS-123 and IMCAS-364 antibodies, according to the characteristic of the molecular distance of 90 angstroms of three RBD epitopes on the surface S protein trimer of the new coronavirus, the span of the traditional IgG1 form antibody is considered to be 150 angstroms, and bivalent combination cannot be formed in one trimer molecule. According to the literature, a single-chain double-specificity construction mode is adopted, the theoretical molecular length is 60-70 angstroms, the two RBDs can be effectively embedded into a trimer, and in the process of combining the virus and a receptor, due to the fact that the two RBDs are combined by the double-specificity molecules, the conformational change is locked, and invasion blocking is achieved.
In the construction process, based on a reference for constructing a Tand form dimer tetravalent antibody molecule in an escherichia coli system, the defect that a large number of single-chain spontaneous folds generated by a long Linker can not be efficiently paired with double chains is mentioned, and the construction is carried out by reversely utilizing the defect of the single-chain spontaneous folds and respectively based on two light and heavy chain variable region sequences of known IMCAS-123 and IMCAS-364
Key part maps were constructed as follows: EcoRI enzyme cutting site-GCCACC-signal peptide-364 VH-linker1-123VL-linker2-123VH-linker1-364VL-SfiI-6 xHis-stop codon-enzyme cutting site XhoI, the construction adopts a gene synthesis mode, the codon optimization according to a 293F expression system is completed by Nanjing Kinshire company, the gene synthesis is completed by the same company through EcoRI and XhoI and connected into pcaggs expression vector, and the constructed plasmid is returned.
EXAMPLE two bispecific antibody Tandab123-64 purification procedure
(I) plasmid transformation
(1) Taking out Top 10 competent cells from a-80 ℃ refrigerator, and carrying out ice bath for 10 min;
(2) 0.1ug of plasmid was placed in 30 μ L of competent cells, the contents were gently swirled and mixed, ice-washed for 30 min;
(3) heat shock at 42 ℃ for 90s in ice bath for 3min without shaking the centrifuge tube;
(4) adding 500 μ L of non-resistant LB culture medium preheated at 37 ℃ into each centrifuge tube, and performing constant temperature shaking culture at 180rpm and 37 ℃ for 30 min;
(5) coating 100 mu L of bacterial liquid in an LB solid culture medium containing Amp, positively placing a flat plate for 2-3 hours at 37 ℃, and then performing inverted culture for 16-24 hours;
(6) single colonies of a suspected positive clone were selected, inoculated into an LB medium (4 mL/tube) containing Amp, and subjected to shaking culture at 37 ℃ and 200rpm for 12 to 16 hours.
(II) plasmid extraction
(1) Adding 3mL of culture solution after the positive clone culture into an LB culture medium containing 1 per mill of ampicillin, and carrying out constant temperature overnight shaking culture at 180rpm and 37 ℃;
(2) centrifuging the cultured bacterial liquid, removing the supernatant, and collecting the precipitate;
(3) carrying out large plasmid extraction by using an endotoxin-free plasmid large-plasmid extraction kit of Tiangen company according to the instruction;
(4) and (3) carrying out nucleic acid electrophoresis identification on the greatly extracted plasmid, measuring the concentration, and temporarily storing the plasmid in a refrigerator at the temperature of-20 ℃ for later use.
(III) transfection of 293F cells
(1) Transfection buffer: 20mM HAPES, 150mM NaCl, pH 7.4; transfection reagent: PEI;
(2) according to the proportion of 1ug of plasmid transfected by 1mL of cells, 500ug of plasmid was dissolved in a transfection buffer, and the total volume was 12.5mL, according to the PEI: dissolving PEI in the same solution at a ratio of 3:1 to 12.5mL, and standing for 5 min;
(3) mixing the two solutions, and standing for 15 min;
(4) the mixed solution after standing was slowly dropped into 500mL of a pipette tip with a density of 3X 10 6 cells/mL 293F cells, in the process, the cells were shaken while dropping;
(5) placing the transfected cells into a CO-impermeable container 2 The cells were cultured in the shaker for 24 hours, then taken out, added with 17.5mL of the feed solution, cultured for 48 hours, added with the feed solution again, transfected for 5 days, and then harvested for protein purification.
(IV) protein purification
1. Cell Collection and Pre-treatment
293F cells are collected by a high-speed refrigerated centrifuge, centrifuged at 6500rpm/min at 8 ℃ for 90min to discard precipitates, and a supernatant is collected and filtered by a 0.22 mu m filter to remove impurities.
2. Ni-NTA affinity chromatography column
Using a peristaltic pump, the HisTrap was equilibrated with 25mL (5 column volumes) of water and affinity chromatography buffer A (20mM Tris, 150mM NaCl, pH 8.0), respectively TM And (4) an HP affinity chromatographic column, wherein all supernatant flows through the chromatographic column at the flow rate of 2mL/min after the balance is good, and the lower liquid is collected. And (2) introducing the His column combined with the target protein into an AKTA chromatographic system, mixing the solution A and the solution B (20mM Tris, 150mM NaCl, 1M imidazole and pH 8.0) according to different proportions, performing gradient elution on the affinity column, wherein the concentrations of the imidazole are 0, 20, 50, 100, 300, 500mM and 1M respectively, collecting samples eluted at different imidazole concentrations respectively, and identifying by SDS-PAGE.
3. Gel filtration chromatography
According to the difference of molecular mass and shape, the separation and purification are carried out by a method of Gel filtration chromatography (GF). Hiload 16/600Superdex200 PG (200 size for short) is selected as Tandab123-64 according to the molecular weight.
Concentrating the target protein eluted by His affinity chromatography by using a 10kDa ultrafiltration tube, changing the solution into a PBS solution, centrifuging at 4 ℃ for 10min at 12000rpm/min for 3 times to remove precipitates, injecting the solution into a molecular sieve through a 2mL loop ring, flowing the solution through the molecular sieve at the flow rate of 1mL/min, and collecting a sample with the UV280 value of more than 5mAU according to the volume of 1.8mL per tube. The collected samples were run on SDS-PAGE and concentrated by selecting sample tubes based on the electrophoresis results, peak positions and peak shapes (as shown in FIG. 1). Subpackaging the concentrated protein, quickly freezing with liquid nitrogen, and storing in a refrigerator at-80 deg.C. After 120mL of buffer is sieved, 1 column volume of water and 20% ethanol are added, and the mixture is stored at room temperature.
EXAMPLE III detection of protein and antibody affinity (biacore) by surface plasmon resonance
The surface plasmon resonance phenomenon is utilized to detect the intermolecular interaction, and the detection is completed on a biomacromolecule interaction analysis system Biacore 8K produced by GE Healthcare group. The prototype strain virus receptor binding domain protein, the beta variant strain virus receptor binding domain protein, the delta variant strain virus receptor binding domain protein, the ormickron variant strain (subtypes ba.1, ba.2, ba.3 and ba.1.1) virus receptor binding domain protein and the atypical pneumovirus receptor binding domain protein were captured using biotin-streptavidin coupling (SA chip) as stationary phases, mobile phase was Tandab123-64 neo-corona bispecific neutralizing antibody protein to be detected, after which kinetic parameters were analyzed by BIA evaluation software and plotted.
The experimental steps are as follows: utilizing the coupling effect of biotin-streptavidin, firstly, the original strain virus receptor binding domain protein, the beta variant strain virus receptor binding domain protein, the delta variant strain virus receptor binding domain protein, the Onckronk variant strain (BA.1, BA.2, BA.3 and BA.1.1 subtypes) virus receptor binding domain protein and the atypical pneumonia virus receptor binding domain protein are proportionally placed with a biotinylation reagent at room temperature for 30 minutes, the protein is biotinylated and labeled, and then the liquid is changed to PBS by a concentration tube, so that the redundant biotinylation reagent is removed. Biotinylated antigenic protein prototype strain viral receptor binding domain protein, beta variant viral receptor binding domain protein, delta variant viral receptor binding domain protein, omchon variant (subtypes ba.1, ba.2, ba.3, and ba.1.1) viral receptor binding domain protein, and atypical pneumovirus receptor binding domain protein were immobilized on an SA chip (GE) at a concentration of 10 μ g/ml, and antibody Tandab123-64 was injected into the chip at a concentration gradient of 2.5nM, 5nM, 10nM, 20nM, and 40nM, and the assay was performed at a constant temperature of 25 ℃ using 0.05% PBST. The regeneration of the chip surface was carried out using a 10mM Glynice solution pH 1.7. Binding curves are shown, and curves at different concentrations make up the illustrated kinetic curves. The calculation of binding kinetic constants was performed using BIA evaluation software version 3.2(Biacore, Inc.) software.
The results are shown in FIG. 2, wherein it is known that the constructed bispecific antibody Tand ab123-64 can realize strong protection of all subtypes of the mutant strain Ornken to BA.1 (0.04. mu.g/ml), BA.2 (0.05. mu.g/ml), BA.3 (0.04. mu.g/ml) and BA.1.1 (0.08. mu.g/ml).
EXAMPLE four neutralization experiments of antibody Tand ab123-64 and SARS-CoV-2 pseudovirus
Firstly, a preparation part:
sample preparation: tandab123-64 bispecific neutralizing antibody
Pseudoviruses (prototype strain, alpha variant, beta variant, delta variant, gamma variant, Ormcken variant (subtypes BA.1, BA.2, BA.3 and BA.1.1), atypical pneumonia strains
Consumable material: gun head (sterile), round bottom 96-well plate, 10cm cell culture dish, flat bottom 12-well plate, flat bottom 96-well plate, flow type stationary liquid, flow type tube
Reagent: DMEM Medium + 10% FBS (044)
Secondly, pseudovirus packaging:
pCAGGS-SARS-CoV-2-S mutant plasmid 30. mu.g each, 293T cell transfection 10cm2 dish (cell amount 80% -90%), liquid exchange DMEM (10% FBS) after 4h, VSV-delta G-GFP pseudovirus 5ml after 24h transfection, liquid exchange after 2h, DMEM 10%, VSVG-containing antibody 1:1000(10mg/ml from I1 Hybridoma)CRL2700 TM Cell expression, final concentration 10. mu.g/ml), supernatant was collected 20h after pseudovirus addition, centrifuged at 3000rpm for 10min, and filtered through 0.45 filter. Subpackaging the jelly-80. Cells that were not transfected with S protein, and subsequent groups to which VSV-. DELTA.G-GFP pseudovirus and antibody were also added as pseudovirus packaging controls.
Thirdly, quantification of pseudovirion:
pseudoviruses were treated with 0.5U/. mu.l BaseMauncher endonuclease (Abcam, ab270049) for 1.5 hours.
RNA was extracted and QPCR was performed using primers for L protein. And performing a unification process according to the result.
Fourthly, determination of pseudovirus titer:
spreading vero cells in a 96-well plate for 24 hours to 90 percent;
pseudovirus was diluted with DMEM (containing 10% 044FBS) 3-fold gradient, 100 μ l/well in 96-well plates, and triplicate wells were made for each sample;
after 15h, the readings were photographed using a CQ 1-dual turntable laser confocal cell imaging analysis system to calculate titer.
And fifthly, neutralization experiment:
spreading vero cells in a 96-well plate for 24 hours to 90 percent; inactivated serum was removed from-80 ℃ on the day of the experiment and thawed on ice (serum inactivated 30min at 56 ℃ in advance). Antibodies (initial 40. mu.g/ml) were diluted in DMEM medium (containing 10% 044FBS) (2 replicates, 4-fold dilution, 10 gradients) while pseudoviruses were diluted to 1000 TU/50. mu.l/assoy with the same DMEM medium.
The diluted antibody and pseudovirus were added to a 96-well plate (volume ratio 1:1, i.e. 1 replicate well 60. mu.l antibody dilution + 60. mu.l pseudovirus dilution), and mixed by pipetting 1 time. Putting the 96-well plate into a temperature of 37 ℃ for incubation for 1 h; and (3) incubating for 40-50min, taking out the vero cells prepared in the incubator in advance, completely sucking the supernatant of the vero cells, adding 100 mu l of mixed diluent of the antibody and the virus, incubating for 15h at 37 ℃, detecting green fluorescence by using a CQ 1-double turntable laser confocal cell imaging analysis system reading method, photographing, counting, and processing data by using GraphpadPrism9.3.1 software.
The experimental results are shown in fig. 3, in which the half-maximal inhibition ratios are as follows:
PT | Alpha | Beta | Delta | Gamma | BA.1 | BA.2 | BA.3 | BA.1.1 | SARS |
0.01876 | 0.02149 | 0.02560 | 0.1090 | 0.01488 | 0.04595 | 0.05193 | 0.03779 | 0.08199 | 18.05 |
therefore, the bispecific antibody Tand ab123-64 constructed by the invention can be used as an effective antibody medicament for efficiently resisting all the existing new crown mutation strains and future new crown mutation strains.
<110> institute of microbiology, national academy of sciences; shanxi institute of advanced innovation
<120> a potent anti-new crown mutation strain comprising four subtypes of human bispecific antibody of Ormcken
<160>28
<170>PatentIn version 3.5
<210> 1
<211> 8
<212> PRT
<213> Artificial sequence
<400> 1
GFTFSRYG 8
<210> 2
<211> 8
<212> PRT
<213> Artificial sequence
<400> 2
IWYDGSNK 8
<210> 3
<211> 19
<212> PRT
<213> Artificial sequence
<400> 3
AKQEGTYCSGGSCYSGLDY 19
<210> 4
<211> 6
<212> PRT
<213> Artificial sequence
<400> 4
QSISSY 6
<210> 5
<211> 3
<212> PRT
<213> Artificial sequence
<400> 5
AAS 3
<210> 6
<211> 9
<212> PRT
<213> Artificial sequence
<400> 6
QQSYSTPLT 9
<210> 7
<211> 8
<212> PRT
<213> Artificial sequence
<400> 7
GFTFSSYA 8
<210> 8
<211> 8
<212> PRT
<213> Artificial sequence
<400> 8
ISGSGGST 8
<210> 9
<211> 17
<212> PRT
<213> Artificial sequence
<400> 9
AKDHLITMVQPEYFHHW 17
<210> 10
<211> 6
<212> PRT
<213> Artificial sequence
<400> 10
QGISRW 6
<210> 11
<211> 3
<212> PRT
<213> Artificial sequence
<400> 11
AAG 3
<210> 12
<211> 7
<212> PRT
<213> Artificial sequence
<400> 12
CQQADSF 7
<210> 13
<211> 128
<212> PRT
<213> Artificial sequence
<400> 13
QVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSAS 128
<210> 14
<211> 108
<212> PRT
<213> Artificial sequence
<400> 14
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKG 108
<210> 15
<211> 125
<212> PRT
<213> Artificial sequence
<400> 15
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSAS 125
<210> 16
<211> 108
<212> PRT
<213> Artificial sequence
<400> 16
DIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKG 108
<210> 17
<211> 12
<212> PRT
<213> Artificial sequence
<400> 17
RADAAAAGGPGS 12
<210> 18
<211> 27
<212> PRT
<213> Artificial sequence
<400> 18
RADAAAAGGGGSGGGGSGGGGSGGGGS 27
<210> 19
<211> 532
<212> PRT
<213> Artificial sequence
<400> 19
QVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSASRADAAAAGGPGSDIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKGRADAAAAGGGGSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSASRADAAAAGGPGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKGTKGPSVTSGQAGQ 532
<210> 20
<211> 21
<212> PRT
<213> Artificial sequence
<400> 20
METDTLLLWVLLLWVPGSTGD 21
<210> 21
<211> 559
<212> PRT
<213> Artificial sequence
<400> 21
METDTLLLWVLLLWVPGSTGDQVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSASRADAAAAGGPGSDIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKGRADAAAAGGGGSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSASRADAAAAGGPGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKGTKGPSVTSGQAGQHHHHHH 559
<210> 22
<211> 1596
<212> DNA
<213> Artificial sequence
<400> 22
ATGCAGGTGCAGCTGCAAGAGAGCGGCGGCGGTGTCGTGCAGCCTGGCCGGAGCCTGAGACTGAGCTGCGCCGCTAGCGGCTTCACCTTTTCTAGATACGGCATGCACTGGGTGAGACAGGCTCCTGGCAAGGGGCTGGAATGGGTGGCCGTGATCTGGTACGACGGCTCCAACAAGTACTACGCCGATAGCGTGAAGGGCAGATTCACCATCTCCCGGGACAACAGCAAAAATACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGACGACACGGCCGTGTACTACTGCGCCAAACAGGAGGGCACATATTGCAGCGGCGGAAGCTGCTACAGCGGACTGGACTACTGGGGACAGGGCACACTGGTGACCGTGAGCAGCGCTTCTCGGGCCGATGCCGCTGCTGCCGGCGGCCCCGGCTCTGATATCCAGATGACCCAGTCCCCAAGCTCTGTGAGCGCCTCTGTTGGCGACAGCGTGACAATCACATGCCGCGCCAGCCAGGGCATCAGCAGATGGCTGGCCTGGTATCAGCAAAGACCTGGCAAGGCCCCTAAACTGCTGATCTACGCCGCTGGGAACCTGGAAACCGGCGTGCCTAGCAGGTTCAGCGGCTCCGGTAGCGGCACCGACTTTACACTTACCATCAGCGACCTGCAAGCAGAGGACTTCGCCACATACTATTGTCAGCAGGCCGACTCATTCCCCCTGACCTTCGGCGGCGGCACAAAGGTGGACATTAAGGGCAGAGCCGACGCCGCGGCCGCCGGCGGAGGAGGCTCGGGCGGCGGAGGTAGCGGCGGCGGAGGTTCTGGAGGCGGCGGCTCACAGGTGCAGCTGGTCGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTCAGACTGAGCTGTGCCGCCAGCGGATTCACCTTTAGTAGCTACGCCATGAGCTGGGTTAGACAGGCCCCTGGCAAAGGCCTGGAGTGGGTGTCCGCCATCAGCGGCTCCGGAGGCAGCACCTACTACGCCGACAGCGTCAAGGGCAGATTTACCATCAGCAGAGATAATAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTCCGGGCCGAAGATACCGCTGTGTACTACTGTGCCAAGGACCACCTGATCACCATGGTGCAGCCCGAGTACTTCCACCACTGGGGCCAAGGAACCCTGGTGACAGTGTCTTCCGCCAGCAGAGCCGATGCCGCCGCCGCCGGCGGACCCGGCGACATTCAGATGACACAGAGCCCTTCTTCTCTGTCTGCTTCTGTCGGCGATCGGGTGACCATCACCTGCAGAGCCAGCCAGAGCATCTCCAGCTACCTGAACTGGTACCAGCAAAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACGCGGCCTCTAGCCTGCAGAGCGGAGTGCCCAGCCGGTTCAGCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAACCTGAGGACTTCGCCACATACTACTGCCAGCAGAGTTATAGCACACCTCTGACCTTCGGCGGTGGAACAAAGGTGGACATCAAGGGTACCAAGGGCCCTAGCGTGACCAGCGGCCAGGCCGGC 1596
<210> 23
<211> 1680
<212> DNA
<213> Artificial sequence
<400> 23
ATGGAAACTGACACCCTGCTGCTCTGGGTGCTGCTGCTGTGGGTGCCAGGCTCTACCGGAGATCAGGTGCAGCTGCAAGAGAGCGGCGGCGGTGTCGTGCAGCCTGGCCGGAGCCTGAGACTGAGCTGCGCCGCTAGCGGCTTCACCTTTTCTAGATACGGCATGCACTGGGTGAGACAGGCTCCTGGCAAGGGGCTGGAATGGGTGGCCGTGATCTGGTACGACGGCTCCAACAAGTACTACGCCGATAGCGTGAAGGGCAGATTCACCATCTCCCGGGACAACAGCAAAAATACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGACGACACGGCCGTGTACTACTGCGCCAAACAGGAGGGCACATATTGCAGCGGCGGAAGCTGCTACAGCGGACTGGACTACTGGGGACAGGGCACACTGGTGACCGTGAGCAGCGCTTCTCGGGCCGATGCCGCTGCTGCCGGCGGCCCCGGCTCTGATATCCAGATGACCCAGTCCCCAAGCTCTGTGAGCGCCTCTGTTGGCGACAGCGTGACAATCACATGCCGCGCCAGCCAGGGCATCAGCAGATGGCTGGCCTGGTATCAGCAAAGACCTGGCAAGGCCCCTAAACTGCTGATCTACGCCGCTGGGAACCTGGAAACCGGCGTGCCTAGCAGGTTCAGCGGCTCCGGTAGCGGCACCGACTTTACACTTACCATCAGCGACCTGCAAGCAGAGGACTTCGCCACATACTATTGTCAGCAGGCCGACTCATTCCCCCTGACCTTCGGCGGCGGCACAAAGGTGGACATTAAGGGCAGAGCCGACGCCGCGGCCGCCGGCGGAGGAGGCTCGGGCGGCGGAGGTAGCGGCGGCGGAGGTTCTGGAGGCGGCGGCTCACAGGTGCAGCTGGTCGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTCAGACTGAGCTGTGCCGCCAGCGGATTCACCTTTAGTAGCTACGCCATGAGCTGGGTTAGACAGGCCCCTGGCAAAGGCCTGGAGTGGGTGTCCGCCATCAGCGGCTCCGGAGGCAGCACCTACTACGCCGACAGCGTCAAGGGCAGATTTACCATCAGCAGAGATAATAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTCCGGGCCGAAGATACCGCTGTGTACTACTGTGCCAAGGACCACCTGATCACCATGGTGCAGCCCGAGTACTTCCACCACTGGGGCCAAGGAACCCTGGTGACAGTGTCTTCCGCCAGCAGAGCCGATGCCGCCGCCGCCGGCGGACCCGGCGACATTCAGATGACACAGAGCCCTTCTTCTCTGTCTGCTTCTGTCGGCGATCGGGTGACCATCACCTGCAGAGCCAGCCAGAGCATCTCCAGCTACCTGAACTGGTACCAGCAAAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACGCGGCCTCTAGCCTGCAGAGCGGAGTGCCCAGCCGGTTCAGCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAACCTGAGGACTTCGCCACATACTACTGCCAGCAGAGTTATAGCACACCTCTGACCTTCGGCGGTGGAACAAAGGTGGACATCAAGGGTACCAAGGGCCCTAGCGTGACCAGCGGCCAGGCCGGCCAGCACCATCACCACCACCACTGA 1680
<210> 24
<211> 17
<212> PRT
<213> Artificial sequence
<400> 24
AKDHLSTMVQPEYFHHW 17
<210> 25
<211> 17
<212> PRT
<213> Artificial sequence
<400> 25
AKDHLMTMVQPEYFHHW 17
<210> 26
<211> 17
<212> PRT
<213> Artificial sequence
<400> 26
AKDHLITLVQPEYFHHW 17
<210> 27
<211> 17
<212> PRT
<213> Artificial sequence
<400> 27
AKDHFITMVQPEYFHHW 17
<210> 28
<211> 17
<212> PRT
<213> Artificial sequence
<400> 28
AKDHFITMVQPEYFYHW 17
Claims (10)
1. A strong double-specific humanized antibody of anti-new crown mutation strain is formed by connecting a first antibody heavy chain, a second antibody light chain and a first antibody heavy chain by a connecting peptide linker;
wherein the heavy chain variable region of said first antibody comprises the amino acid sequence of CDR 1: SEQ ID NO. 1: GFTFSRYG; the CDR2 amino acid sequence is SEQ ID NO. 2: IWYDGSNK; the CDR3 amino acid sequence is SEQ ID No. 3: AKQEGTYCSGGSCYSGLDY, respectively; the variable region of the light chain of the first antibody (IMCAS-364) comprises the CDR1 amino acid sequence of SEQ ID No. 4: QSISSY; the CDR2 amino acid sequence is SEQ ID No. 5: AAS; the CDR3 amino acid sequence is SEQ ID NO. 6: QQSYSTPLT, respectively;
the variable region of the second antibody heavy chain comprises the amino acid sequence of CDR 1: SEQ ID NO. 7: GFTFSSYA; the CDR2 amino acid sequence is SEQ ID NO. 8: ISGSGGST; the CDR3 amino acid sequence is SEQ ID NO. 9: AKDHLITMVQPEYFHHW, SEQ ID NO. 24: AKDHLSTMVQPEYFHHW,SEQ ID NO.25:AKDHLMTMVQPEYFHHW,SEQ ID NO.26:AKDHLITLVQPEYFHHW, SEQ ID NO. 27: AKDHFITMVQPEYFHHW, SEQ ID NO. 28: AKDHFITMVQPEYFYHW, respectively; the light chain variable region of the second antibody comprises the CDR1 amino acid sequence of SEQ ID No. 10: QGISRW; the CDR2 amino acid sequence is SEQ ID NO. 11: AAG; the CDR3 amino acid sequence is SEQ ID No. 12: CQADSSF.
2. The bispecific humanized antibody against a neocrown mutant strain according to claim 1, wherein more preferably the variable region amino acid sequence of the heavy chain of the first antibody is SEQ ID No. 13: QVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSAS, respectively; the variable region amino acid sequence of the light chain of the second antibody is SEQ ID No. 14: DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKG, respectively;
the variable region amino acid sequence of the heavy chain of the second antibody is SEQ ID No. 15: QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSAS; the variable region amino acid sequence of the light chain of the second antibody is SEQ ID No. 16: DIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKG are provided.
3. The bispecific humanized antibody against a new crown mutant strain of claim 1 or 2, wherein the connection mode is formed by connecting a first antibody heavy chain, a linker1, a second antibody light chain, a linker2, a second antibody heavy chain, a linker1 and the first antibody light chain in sequence; preferably, the amino acid sequence of Linker1 is SEQ ID NO. 17: RADAAAAGGPGS, respectively; the amino acid sequence of Linker2 is SEQ ID NO. 18: RADAAAAGGGGSGGGGSGGGGSGGGGS are provided.
4. The bispecific humanized antibody against a novel crown mutation strain according to claim 3, wherein the amino acid sequence of the bispecific humanized antibody against a novel crown mutation strain is SEQ ID No. 19:
QVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSASRADAAAAGGPGSDIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKGRADAAAAGGGGSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSASRADAAAAGGPGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKGTKGPSVTSGQAGQ。
5. the bispecific humanized antibody against the novel crown mutation strain of claim 3, which further comprises a signal peptide, wherein the signal peptide, the first antibody heavy chain, the linker1, the second antibody light chain, the linker2, the second antibody heavy chain, the linker1 and the first antibody light chain are connected in sequence; preferably, the amino acid sequence of the signal peptide is SEQ ID No. 20: METDTLLLWVLLLWVPGSTGD; even more preferably, it further comprises a tag sequence for isolation and purification, such as a 6 × His tag.
6. The bispecific humanized antibody against the novel crown mutation strain of claim 5, wherein the amino acid sequence of the bispecific humanized antibody against the novel crown mutation strain is SEQ ID NO. 21:
METDTLLLWVLLLWVPGSTGDQVQLQESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKQEGTYCSGGSCYSGLDYWGQGTLVTVSSASRADAAAAGGPGSDIQMTQSPSSVSASVGDSVTITCRASQGISRWLAWYQQRPGKAPKLLIYAAGNLETGVPSRFSGSGSGTDFTLTISDLQAEDFATYYCQQADSFPLTFGGGTKVDIKGRADAAAAGGGGSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHLITMVQPEYFHHWGQGTLVTVSSASRADAAAAGGPGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKGTKGPSVTSGQAGQHHHHHH。
7. nucleic acid encoding the bispecific humanized antibody against a novel crown mutation strain according to any one of claims 1 to 6; preferably, the nucleotide sequence is SEQ ID No. 22:
ATGCAGGTGCAGCTGCAAGAGAGCGGCGGCGGTGTCGTGCAGCCTGGCCGGAGCCTGAGACTGAGCTGCGCCGCTAGCGGCTTCACCTTTTCTAGATACGGCATGCACTGGGTGAGACAGGCTCCTGGCAAGGGGCTGGAATGGGTGGCCGTGATCTGGTACGACGGCTCCAACAAGTACTACGCCGATAGCGTGAAGGGCAGATTCACCATCTCCCGGGACAACAGCAAAAATACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGACGACACGGCCGTGTACTACTGCGCCAAACAGGAGGGCACATATTGCAGCGGCGGAAGCTGCTACAGCGGACTGGACTACTGGGGACAGGGCACACTGGTGACCGTGAGCAGCGCTTCTCGGGCCGATGCCGCTGCTGCCGGCGGCCCCGGCTCTGATATCCAGATGACCCAGTCCCCAAGCTCTGTGAGCGCCTCTGTTGGCGACAGCGTGACAATCACATGCCGCGCCAGCCAGGGCATCAGCAGATGGCTGGCCTGGTATCAGCAAAGACCTGGCAAGGCCCCTAAACTGCTGATCTACGCCGCTGGGAACCTGGAAACCGGCGTGCCTAGCAGGTTCAGCGGCTCCGGTAGCGGCACCGACTTTACACTTACCATCAGCGACCTGCAAGCAGAGGACTTCGCCACATACTATTGTCAGCAGGCCGACTCATTCCCCCTGACCTTCGGCGGCGGCACAAAGGTGGACATTAAGGGCAGAGCCGACGCCGCGGCCGCCGGCGGAGGAGGCTCGGGCGGCGGAGGTAGCGGCGGCGGAGGTTCTGGAGGCGGCGGCTCACAGGTGCAGCTGGTCGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTCAGACTGAGCTGTGCCGCCAGCGGATTCACCTTTAGTAGCTACGCCATGAGCTGGGTTAGACAGGCCCCTGGCAAAGGCCTGGAGTGGGTGTCCGCCATCAGCGGCTCCGGAGGCAGCACCTACTACGCCGACAGCGTCAAGGGCAGATTTACCATCAGCAGAGATAATAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTCCGGGCCGAAGATACCGCTGTGTACTACTGTGCCAAGGACCACCTGATCACCATGGTGCAGCCCGAGTACTTCCACCACTGGGGCCAAGGAACCCTGGTGACAGTGTCTTCCGCCAGCAGAGCCGATGCCGCCGCCGCCGGCGGACCCGGCGACATTCAGATGACACAGAGCCCTTCTTCTCTGTCTGCTTCTGTCGGCGATCGGGTGACCATCACCTGCAGAGCCAGCCAGAGCATCTCCAGCTACCTGAACTGGTACCAGCAAAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACGCGGCCTCTAGCCTGCAGAGCGGAGTGCCCAGCCGGTTCAGCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAACCTGAGGACTTCGCCACATACTACTGCCAGCAGAGTTATAGCACACCTCTGACCTTCGGCGGTGGAACAAAGGTGGACATCAAGGGTACCAAGGGCCCTAGCGTGACCAGCGGCCAGGCCGGC;
or SEQ ID NO. 23:
ATGGAAACTGACACCCTGCTGCTCTGGGTGCTGCTGCTGTGGGTGCCAGGCTCTACCGGAGATCAGGTGCAGCTGCAAGAGAGCGGCGGCGGTGTCGTGCAGCCTGGCCGGAGCCTGAGACTGAGCTGCGCCGCTAGCGGCTTCACCTTTTCTAGATACGGCATGCACTGGGTGAGACAGGCTCCTGGCAAGGGGCTGGAATGGGTGGCCGTGATCTGGTACGACGGCTCCAACAAGTACTACGCCGATAGCGTGAAGGGCAGATTCACCATCTCCCGGGACAACAGCAAAAATACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGACGACACGGCCGTGTACTACTGCGCCAAACAGGAGGGCACATATTGCAGCGGCGGAAGCTGCTACAGCGGACTGGACTACTGGGGACAGGGCACACTGGTGACCGTGAGCAGCGCTTCTCGGGCCGATGCCGCTGCTGCCGGCGGCCCCGGCTCTGATATCCAGATGACCCAGTCCCCAAGCTCTGTGAGCGCCTCTGTTGGCGACAGCGTGACAATCACATGCCGCGCCAGCCAGGGCATCAGCAGATGGCTGGCCTGGTATCAGCAAAGACCTGGCAAGGCCCCTAAACTGCTGATCTACGCCGCTGGGAACCTGGAAACCGGCGTGCCTAGCAGGTTCAGCGGCTCCGGTAGCGGCACCGACTTTACACTTACCATCAGCGACCTGCAAGCAGAGGACTTCGCCACATACTATTGTCAGCAGGCCGACTCATTCCCCCTGACCTTCGGCGGCGGCACAAAGGTGGACATTAAGGGCAGAGCCGACGCCGCGGCCGCCGGCGGAGGAGGCTCGGGCGGCGGAGGTAGCGGCGGCGGAGGTTCTGGAGGCGGCGGCTCACAGGTGCAGCTGGTCGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTCAGACTGAGCTGTGCCGCCAGCGGATTCACCTTTAGTAGCTACGCCATGAGCTGGGTTAGACAGGCCCCTGGCAAAGGCCTGGAGTGGGTGTCCGCCATCAGCGGCTCCGGAGGCAGCACCTACTACGCCGACAGCGTCAAGGGCAGATTTACCATCAGCAGAGATAATAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTCCGGGCCGAAGATACCGCTGTGTACTACTGTGCCAAGGACCACCTGATCACCATGGTGCAGCCCGAGTACTTCCACCACTGGGGCCAAGGAACCCTGGTGACAGTGTCTTCCGCCAGCAGAGCCGATGCCGCCGCCGCCGGCGGACCCGGCGACATTCAGATGACACAGAGCCCTTCTTCTCTGTCTGCTTCTGTCGGCGATCGGGTGACCATCACCTGCAGAGCCAGCCAGAGCATCTCCAGCTACCTGAACTGGTACCAGCAAAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACGCGGCCTCTAGCCTGCAGAGCGGAGTGCCCAGCCGGTTCAGCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAACCTGAGGACTTCGCCACATACTACTGCCAGCAGAGTTATAGCACACCTCTGACCTTCGGCGGTGGAACAAAGGTGGACATCAAGGGTACCAAGGGCCCTAGCGTGACCAGCGGCCAGGCCGGCCAGCACCATCACCACCACCACTGA。
8. an expression vector or recombinant cell comprising the nucleic acid of claim 7.
9. The use of the bispecific humanized antibody against a novel crown mutation strain according to any one of claims 1 to 6 for the preparation of a medicament for the treatment of a disease caused by a novel coronavirus selected from the group consisting of SARS-CoV-2, SARS strain; more preferably, said SARS-CoV-2 is selected from the group consisting of a prototype strain, an alpha variant, a beta variant, a delta variant, a gamma variant, an Onckronk variant (more specifically subtypes BA.1, BA.2, BA.3 and BA.1.1).
10. Pharmaceutical composition for the treatment of diseases caused by a new coronavirus containing the bispecific humanized antibody against a new crown mutation strain as potent as described in any one of claims 1 to 6, preferably said new coronavirus is selected from the group consisting of SARS-CoV-2, SARS strain; more preferably, said SARS-CoV-2 is selected from the group consisting of a prototype strain, an alpha variant, a beta variant, a delta variant, a gamma variant, an Onckronk variant (more specifically subtypes BA.1, BA.2, BA.3 and BA.1.1).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210421123.7A CN114907484B (en) | 2022-04-20 | 2022-04-20 | A bispecific human antibody against neocrown mutation strain including four subtypes of Ormcurone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210421123.7A CN114907484B (en) | 2022-04-20 | 2022-04-20 | A bispecific human antibody against neocrown mutation strain including four subtypes of Ormcurone |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114907484A true CN114907484A (en) | 2022-08-16 |
CN114907484B CN114907484B (en) | 2022-12-09 |
Family
ID=82765427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210421123.7A Active CN114907484B (en) | 2022-04-20 | 2022-04-20 | A bispecific human antibody against neocrown mutation strain including four subtypes of Ormcurone |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114907484B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113527472A (en) * | 2020-04-16 | 2021-10-22 | 深圳市福田区格物智康病原研究所 | Specific antibody of SARS-CoV-2S protein or its fragment and its application |
US20210388065A1 (en) * | 2020-04-15 | 2021-12-16 | Active Motif Shanghai Limited | Antibodies to sars-coronavirus (covid-19) s1 spike protein |
CN113943368A (en) * | 2021-10-15 | 2022-01-18 | 中国科学院微生物研究所 | Novel monoclonal antibody of coronavirus and mutant thereof and application of monoclonal antibody |
CN114031685A (en) * | 2022-01-10 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | Fully human anti-new coronavirus broad-spectrum neutralizing antibody ZW2G10 and application thereof |
CN114292327A (en) * | 2022-03-10 | 2022-04-08 | 中国科学院微生物研究所 | Human antibody of broad-spectrum novel coronavirus and application thereof |
CN114384245A (en) * | 2022-03-24 | 2022-04-22 | 江苏美克医学技术有限公司 | Novel joint inspection kit for identifying double epitopes of S-RBD (S-radial basis function) protein and N protein of coronavirus and application of joint inspection kit |
CN114397452A (en) * | 2022-03-24 | 2022-04-26 | 江苏美克医学技术有限公司 | Novel coronavirus Delta mutant strain or prototype strain detection kit and application thereof |
CN114397453A (en) * | 2022-03-25 | 2022-04-26 | 江苏美克医学技术有限公司 | Detection kit for novel coronavirus mutant strain and application thereof |
CN114395034A (en) * | 2022-03-24 | 2022-04-26 | 中国科学院微生物研究所 | Human antibody for efficiently neutralizing novel coronavirus and application thereof |
CN114456264A (en) * | 2022-03-24 | 2022-05-10 | 中国科学院微生物研究所 | Novel human antibody of rare broad-spectrum epitope of coronavirus and application thereof |
WO2022200291A2 (en) * | 2021-03-23 | 2022-09-29 | Ceinge Biotecnologie Avanzate Scarl | Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2 |
-
2022
- 2022-04-20 CN CN202210421123.7A patent/CN114907484B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210388065A1 (en) * | 2020-04-15 | 2021-12-16 | Active Motif Shanghai Limited | Antibodies to sars-coronavirus (covid-19) s1 spike protein |
CN113527472A (en) * | 2020-04-16 | 2021-10-22 | 深圳市福田区格物智康病原研究所 | Specific antibody of SARS-CoV-2S protein or its fragment and its application |
WO2022200291A2 (en) * | 2021-03-23 | 2022-09-29 | Ceinge Biotecnologie Avanzate Scarl | Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2 |
CN113943368A (en) * | 2021-10-15 | 2022-01-18 | 中国科学院微生物研究所 | Novel monoclonal antibody of coronavirus and mutant thereof and application of monoclonal antibody |
CN114031685A (en) * | 2022-01-10 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | Fully human anti-new coronavirus broad-spectrum neutralizing antibody ZW2G10 and application thereof |
CN114292327A (en) * | 2022-03-10 | 2022-04-08 | 中国科学院微生物研究所 | Human antibody of broad-spectrum novel coronavirus and application thereof |
CN114384245A (en) * | 2022-03-24 | 2022-04-22 | 江苏美克医学技术有限公司 | Novel joint inspection kit for identifying double epitopes of S-RBD (S-radial basis function) protein and N protein of coronavirus and application of joint inspection kit |
CN114397452A (en) * | 2022-03-24 | 2022-04-26 | 江苏美克医学技术有限公司 | Novel coronavirus Delta mutant strain or prototype strain detection kit and application thereof |
CN114395034A (en) * | 2022-03-24 | 2022-04-26 | 中国科学院微生物研究所 | Human antibody for efficiently neutralizing novel coronavirus and application thereof |
CN114456264A (en) * | 2022-03-24 | 2022-05-10 | 中国科学院微生物研究所 | Novel human antibody of rare broad-spectrum epitope of coronavirus and application thereof |
CN114397453A (en) * | 2022-03-25 | 2022-04-26 | 江苏美克医学技术有限公司 | Detection kit for novel coronavirus mutant strain and application thereof |
Non-Patent Citations (2)
Title |
---|
ZHAOHUI LI等: "An engineered bispecific human monoclonal antibody against SARS-CoV-2", 《NATURE IMMUNOLOGY》 * |
郭艺飞等: "严重急性呼吸综合征冠状病毒2Omicron变异株研究", 《微生物与感染》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114907484B (en) | 2022-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101974901B1 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
WO2021244089A1 (en) | Sars-cov-2 spike protein binding molecule and application thereof | |
JP2019520809A5 (en) | ||
Gu et al. | Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting | |
EP2921503B1 (en) | Human anti-human epidemic growth factor receptor antibody and encoding gene and application thereof | |
CN107614762B (en) | Single-chain variant fragment antibody library expressed by phage | |
Wang et al. | Development of therapeutic antibodies for the treatment of diseases | |
AU2018266091B2 (en) | Multispecific protein drug and library thereof, preparing method therefor and application thereof | |
WO2022143816A1 (en) | Full-human broad-spectrum cross-neutralizing antibody for sars-cov-2 and sars-cov and application thereof | |
WO2021218684A1 (en) | Tetravalent bispecific antibody, preparation method therefor, and use thereof | |
KR20210107747A (en) | Antibody fusion protein, preparation method thereof and application thereof | |
WO2022061594A1 (en) | Sars-cov-2 spike protein binding molecule and use thereof | |
JP2023526977A (en) | CD40 binding protein | |
CN114907484B (en) | A bispecific human antibody against neocrown mutation strain including four subtypes of Ormcurone | |
CN115038718A (en) | Antibodies against human programmed death ligand-1 (PD-L1) and uses thereof | |
WO2023279803A1 (en) | Protein binding molecule of rbv and use thereof | |
WO2023273595A1 (en) | Antibody binding to trop2, bispecific antibody targeting trop2 and cd3, preparation methods therefor and uses thereof | |
Borras et al. | Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting | |
WO2024061364A1 (en) | Anti-4-1bb nanobody, preparation therefor, and use thereof | |
CN115109156A (en) | Nanometer antibody targeting BCMA and application thereof | |
Buzas et al. | Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders | |
CN114805584B (en) | Antigen binding proteins and uses thereof | |
CN114805570B (en) | Anti-human ACE2 monoclonal antibody and application thereof | |
CN113004416B (en) | Construction and application of HER2-CD137 targeted bispecific antibody | |
CN113248610B (en) | Interleukin 2 binding molecules, derivatives thereof, kits, methods of production and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |